LRMR Logo.png
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event
September 16, 2021 08:00 ET | Larimar Therapeutics
BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
LRMR Logo.png
Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 02, 2021 16:01 ET | Larimar Therapeutics
BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
LRMR Logo.png
Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress
August 19, 2021 07:00 ET | Larimar Therapeutics
BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
LRMR Logo.png
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
August 12, 2021 07:00 ET | Larimar Therapeutics
- Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreich’s ataxia (FA) - Subcutaneous injections of CTI-1601 at doses of...
LRMR Logo.png
Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021
July 08, 2021 16:01 ET | Larimar Therapeutics
BALA CYNWYD, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
LRMR Logo.png
Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference
June 11, 2021 07:00 ET | Larimar Therapeutics
BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
LRMR Logo.png
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
May 25, 2021 17:41 ET | Larimar Therapeutics
BALA CYNWYD, Pa., May 25, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s...
LRMR Logo.png
Larimar Therapeutics Announces $95 Million Private Placement Financing
May 21, 2021 09:18 ET | Larimar Therapeutics
BALA CYNWYD, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s...
LRMR Logo.png
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
May 20, 2021 16:31 ET | Larimar Therapeutics
BALA CYNWYD, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s...
LRMR Logo.png
Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia
May 11, 2021 07:00 ET | Larimar Therapeutics
Data demonstrate proof-of-concept by showing that daily subcutaneous injections of CTI-1601 for up to 13 days resulted in dose-dependent increases in frataxin levels from baseline compared to placebo...